Literature DB >> 9379032

Alteration of glycosylation renders HIV sensitive to inactivation by normal human serum.

D J Reed1, X Lin, T D Thomas, C W Birks, J Tang, R P Rother.   

Abstract

Retroviruses from various mammalian species, excluding humans, are effectively inactivated in normal human serum (NHS). Recent studies have shown that NHS inactivation of retroviruses occurs through natural Ab recognition of a terminal glycosidic moiety on the viral envelope that is acquired during replication in the host cell. This carbohydrate structure (the alpha-galactosyl epitope) is expressed on the cells of most mammals, with the exception of humans and other Old World primates. In this study, NHS sensitivity of HIV was assessed following viral propagation in human cells that were manipulated to express the alpha-galactosyl epitope. HUT-78 cells were transduced with an exogenous alpha1-3-galactosyl transferase gene, which codes for the terminal glycosyl transferase responsible for generation of the alpha-galactosyl epitope. The transduced HUT-78 cells expressed high levels of the alpha-galactosyl epitope on their membrane surface, rendering them sensitive to killing in NHS. Similarly, HIV passaged through these cells acquired the alpha-galactosyl epitope in association with the envelope glycoprotein gp120 and was also effectively inactivated in NHS. Viral inactivation was abolished by the addition of a synthetic disaccharide that contains the alpha-galactosyl epitope, indicating that virolysis is mediated by anti-alpha-galactosyl natural Ab. These results demonstrate that, like other retroviruses bearing the alpha-galactosyl epitope, HIV modified to express this epitope is inactivated in NHS. Furthermore, these data suggest that expression of the alpha-galactosyl epitope on the surface of viruses may have implications in the interspecies transmission of such viruses to humans.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9379032

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  4 in total

1.  Induction of cytolytic anti-Gal antibodies in alpha-1,3-galactosyltransferase gene knockout mice by oral inoculation with Escherichia coli O86:B7 bacteria.

Authors:  Karla J Posekany; H Keith Pittman; John F Bradfield; Carl E Haisch; Kathryn M Verbanac
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

2.  Reduced sensitivity to human serum inactivation of enveloped viruses produced by pig cells transgenic for human CD55 or deficient for the galactosyl-alpha(1-3) galactosyl epitope.

Authors:  Saema Magre; Yasuhiro Takeuchi; Gillian Langford; Andrew Richards; Clive Patience; Robin Weiss
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

3.  Porcine endogenous retrovirus transmission characteristics of galactose alpha1-3 galactose-deficient pig cells.

Authors:  Gary Quinn; James C Wood; David J J Ryan; Kristen M Suling; Kathleen M Moran; Donna L Kolber-Simonds; Julia L Greenstein; Henk-Jan Schuurman; Robert J Hawley; Clive Patience
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

4.  Evaluation of the Galalpha1-3Gal epitope as a host modification factor eliciting natural humoral immunity to enveloped viruses.

Authors:  R M Welsh; C L O'Donnell; D J Reed; R P Rother
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.